Optiver Holding’s FibroBiologics FBLG Stock Holding History

Optiver Holding’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$6	–	2788
2025 Q4	$6	Hold	1	–	–	﹤0.01%	2433
2025 Q3	$14	Buy	+1	New	+$12	﹤0.01%	2651

Other funds holding FBLG

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Optiver Holding's FBLG Position: Q1 2026 in Review

Optiver Holding sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 1 share — an estimated $6 sold.

Optiver Holding first reported a position in FBLG in Q3 2025 and held it in 2 quarters. The position peaked at $14 in Q3 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Optiver Holding reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Optiver Holding sold 1 FibroBiologics share in Q1 2026, an estimated $6.
Optiver Holding first reported a position in FibroBiologics in Q3 2025 and held it in 2 quarters.
Optiver Holding's FibroBiologics position peaked at $14 in Q3 2025.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.